Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/166338
Sugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed
Matèries (anglès)
Citació
Citació
VIEIRA, Raquel, et al. Sugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I. Pharmaceuticals. 2019. Vol. 12, num. 4, pags. 152. ISSN 1424-8247. [consulted: 11 of August of 2026]. Available at: https://hdl.handle.net/2445/166338